| Basics |
Myriad Genetics, Inc.
Myriad Genetics Inc is a molecular diagnostic company. It develops and markets novel predictive medicine, personalized medicine and prognostic medicine tests. It also provides physicians with information to solve unmet medical needs.
|
| IPO Date: |
October 6, 1995 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$735.05M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.50 | 1.91%
|
| Avg Daily Range (30 D): |
$0.19 | 2.46%
|
| Avg Daily Range (90 D): |
$0.17 | 2.81%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.84M |
| Avg Daily Volume (30 D): |
.99M |
| Avg Daily Volume (90 D): |
1.26M |
| Trade Size |
| Avg Trade Size (Sh.): |
121 |
| Avg Trade Size (Sh.) (30 D): |
72 |
| Avg Trade Size (Sh.) (90 D): |
90 |
| Institutional Trades |
| Total Inst.Trades: |
11,690 |
| Avg Inst. Trade: |
$1.85M |
| Avg Inst. Trade (30 D): |
$1.64M |
| Avg Inst. Trade (90 D): |
$1.44M |
| Avg Inst. Trade Volume: |
.08M |
| Avg Inst. Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.5M |
| Avg Closing Trade (30 D): |
$1.83M |
| Avg Closing Trade (90 D): |
$1.43M |
| Avg Closing Volume: |
107.92K |
|
|
| Financials |
| |
TTM |
Q2 2025 |
Q1 2025 |
|
Basic EPS
|
$-4.28
|
$-3.57
|
$
|
|
Diluted EPS
|
$-4.28
|
$-3.57
|
$
|
|
Revenue
|
$ 832.9M
|
$ 213.1M
|
$ 195.9M
|
|
Gross Profit
|
$ 586.7M
|
$ 151.8M
|
$ 134.2M
|
|
Net Income / Loss
|
$ -395.2M
|
$ -330.5M
|
$ -.1M
|
|
Operating Income / Loss
|
$ -417.2M
|
$ -329.2M
|
$ -29M
|
|
Cost of Revenue
|
$ 246.2M
|
$ 61.3M
|
$ 61.7M
|
|
Net Cash Flow
|
$ -19.8M
|
$ -17.3M
|
$ -10.9M
|
|
PE Ratio
|
|
|
|
| Splits |
|
Mar 26, 2009:
2:1
|
|
Sep 12, 2000:
2:1
|
|
|
|
